BTIG Research Reiterates Buy Rating for Embecta (NASDAQ:EMBC)

Embecta (NASDAQ:EMBC)‘s stock had its “buy” rating restated by research analysts at BTIG Research in a research note issued on Friday,Benzinga reports. They presently have a $25.00 price target on the stock. BTIG Research’s target price suggests a potential upside of 130.20% from the company’s current price.

A number of other research firms also recently weighed in on EMBC. Weiss Ratings reissued a “hold (c-)” rating on shares of Embecta in a research report on Wednesday, January 21st. Wall Street Zen upgraded Embecta from a “buy” rating to a “strong-buy” rating in a research note on Saturday, December 27th. One investment analyst has rated the stock with a Buy rating and three have assigned a Hold rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of $18.50.

Embecta Price Performance

Shares of Embecta stock opened at $10.86 on Friday. The firm has a market cap of $643.02 million, a PE ratio of 4.58 and a beta of 1.11. Embecta has a 1 year low of $9.20 and a 1 year high of $18.07. The stock has a fifty day moving average price of $11.76 and a 200-day moving average price of $12.97.

Embecta (NASDAQ:EMBC) last posted its quarterly earnings results on Thursday, February 5th. The company reported $0.71 earnings per share for the quarter, beating the consensus estimate of $0.67 by $0.04. Embecta had a net margin of 12.92% and a negative return on equity of 26.66%. The company had revenue of $261.20 million during the quarter, compared to analyst estimates of $258.07 million. During the same quarter in the prior year, the business earned $0.65 earnings per share. The firm’s revenue for the quarter was down .3% on a year-over-year basis. Embecta has set its FY 2026 guidance at 2.800-3.00 EPS. As a group, equities analysts anticipate that Embecta will post 2.85 EPS for the current fiscal year.

Institutional Investors Weigh In On Embecta

Several institutional investors have recently made changes to their positions in the stock. Royal Bank of Canada increased its holdings in Embecta by 38.3% during the 1st quarter. Royal Bank of Canada now owns 18,201 shares of the company’s stock worth $232,000 after acquiring an additional 5,036 shares during the period. AQR Capital Management LLC grew its position in shares of Embecta by 3.7% during the 1st quarter. AQR Capital Management LLC now owns 225,641 shares of the company’s stock valued at $2,738,000 after purchasing an additional 8,109 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its position in shares of Embecta by 2.4% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 49,323 shares of the company’s stock valued at $629,000 after purchasing an additional 1,159 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its holdings in shares of Embecta by 4.8% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 172,173 shares of the company’s stock worth $2,195,000 after purchasing an additional 7,894 shares during the period. Finally, Jane Street Group LLC raised its position in shares of Embecta by 224.0% in the first quarter. Jane Street Group LLC now owns 132,688 shares of the company’s stock worth $1,692,000 after buying an additional 91,729 shares in the last quarter. Hedge funds and other institutional investors own 93.83% of the company’s stock.

Key Embecta News

Here are the key news stories impacting Embecta this week:

• Positive Sentiment: Q1 results beat expectations — EPS $0.71 vs. $0.67 consensus and revenue $261.2M vs. $258.1M; management provided slide deck and press release that highlight execution on core products. Embecta Q1 Results
• Positive Sentiment: BTIG reaffirmed a Buy and set a $25 price target (material upside vs. current levels), which can boost investor sentiment and momentum. BTIG Reaffirmation
• Positive Sentiment: Board declared a quarterly cash dividend of $0.15/share (annualized yield ~5.7%) — supports income-focused investors and may attract yield-seeking flows. Dividend Announcement
• Neutral Sentiment: Earnings call materials and transcripts are available (slides, call transcript, presentation) for investors wanting detail on product trends, margin drivers and regional performance; these provide transparency but no new catalyst by themselves. Earnings Presentation
• Negative Sentiment: FY2026 EPS guidance of $2.80–3.00 is modestly below sell‑side consensus (~$2.89), which could cap upside as investors weigh near-term growth headwinds vs. one-time execution positives. Guidance Details

Embecta Company Profile

Embecta Corp (NASDAQ: EMBC) is a pure-play diabetes care company that was spun off from Becton, Dickinson and Company on July 1, 2021. Headquartered in Franklin Lakes, New Jersey, Embecta focuses exclusively on the development, manufacturing and commercialization of products that enable insulin delivery and blood glucose monitoring for people with diabetes.

The company’s product portfolio includes insulin infusion sets, durable and patch pumps, pen needles, infusion tubing, blood glucose test strips, lancets and lancing devices.